Epizyme (EPZM) Tops Q3 EPS by 3c

Epizyme Announces Third Quarter 2015 Financial Results and Provides Corporate Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for cancer patients, today reported business highlights and operating and financial results for the third quarter of 2015.

Epizyme is well-positioned, with tazemetostat achieving proof of concept in both hematological malignancies and genetically defined solid tumors, while demonstrating an acceptable safety profile, said Robert Bazemore, President and Chief Executive Officer, Epizyme. Epizyme is executing on our strategic goal of bringing tazemetostat to patients as quickly as possible, and we are operating from a sound financial... More

Epizyme Announces Presentations at 57th American Society of Hematology Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for cancer patients, announced today that data from the ongoing phase 1 study of tazemetostat (EPZ-6438) will be presented during the American Society of Hematology Meeting being held December 5 8 in Orlando, Florida. Tazemetostat is a first-in-class EZH2 inhibitor that is currently being studied in relapsed or refractory B-cell Non-Hodgkin Lymphoma (NHL) and solid tumors. The company will also present an update on its phase 1 study of pinometostat (EPZ-5676) in adult patients with MLL-r acute leukemia and... More